US EditionBlue Earth’s radioligand therapy achieves high tumour radiation absorption
Summary by Clinical Trials Arena
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Blue Earth’s radioligand therapy achieves high tumour radiation absorption
Results from Blue Earth's Phase I/II radioligand trial showed the injectable therapy to have an effective half-life of 91.4 hours.The post Blue Earth’s radioligand therapy achieves high tumour radiation absorption appeared first on Clinical Trials Arena.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
